Compare TBBK & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | EVO |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.1B |
| IPO Year | 2005 | N/A |
| Metric | TBBK | EVO |
|---|---|---|
| Price | $54.44 | $3.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $69.00 | $7.00 |
| AVG Volume (30 Days) | ★ 399.4K | 48.2K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $8.16 | $10.05 |
| P/E Ratio | $39.10 | ★ N/A |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $49.00 | $2.31 |
| 52 Week High | $81.65 | $4.42 |
| Indicator | TBBK | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 56.89 |
| Support Level | $51.21 | $2.88 |
| Resistance Level | $55.74 | $3.75 |
| Average True Range (ATR) | 1.49 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 45.66 | 100.00 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.